Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Chronic transdermal nicotine has been found to improve attentional performance in patients with Alzheimer’s disease (AD), but little is known about chronic nicotine effects in age-associated memory impairment (AAMI), a milder form of cognitive dysfunction. The current study was performed to determine the clinical and neuropsychological effects of chronic transdermal nicotine in AAMI subjects over a 4-week period.
The double-blind, placebo-controlled, cross-over study consisted of two 4-week periods separated by a 2-week washout period.
An outpatient setting was used.
The subjects (n=11) met criteria for AAMI.
The subjects were given nicotine patches (Nicotrol) to wear for 16 h a day at the following doses: 5 mg/day during week 1, 10 mg/day during week 2 and week 3 and 5 mg/day during week 4.
The effects of nicotine treatment were determined with the clinical global impressions questionnaire, Conners’ Continuous Performance test, and the automated neuropsychologic assessment metrics (ANAM) computerized neuropsychology battery.
Nicotine significantly improved the clinical global impression score as assessed by participants, as well as objective tests of attentional function on the Connors’ Continuous Performance Test and decision reaction time on the neuropsychology test battery. Nicotine did not improve performance on other tests measuring motor and memory function.
Chronic transdermal nicotine treatment in AAMI subjects caused a sustained improvement in clinical symptoms and objective computerized tests of attention. These results support the further investigation of nicotinic treatment as a promising therapy for AAMI.
- Conners CK (1994) The continuous performance test (CPT): use as a diagnostic tool and measure of treatment outcome. Annual convention of the American Psychological Association, Los Angeles, CA, 12–16 August 1994
- Conners CK (1995) The continuous performance test. Multi-Health Systems, Toronto
- Crook T, Bartus T, Ferris S, Whitehouse P (1986) Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of a National Institute of Mental health work group. Dev Neurobiol 2:261–276
- Crook T, Feher E, Larrabee G (1992) Assessment of memory complaints in age-associated memory impairment: The MAC-Q. Int Psychogeriatr 4:165–175
- Epstein JN, Conners CK, Sitarenios G, Erhardt D (1998) Continuous performance test results of adults with attention deficit hyperactivity disorder. Clin Neuropsychol 12:155–168 CrossRef
- Folstein M, Folstein S, McHugh P (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
- Giacobini E, DeSarno P, McIlhany M, Clark B (1988) The cholinergic receptor system in the frontal lobe of Alzheimer’s patients. In: Clementi F, Gotti C, Sher E (eds) Nicotinic acetylcholine receptors in the nervous system. Springer, Berlin Heidelberg New York, pp 367–378
- Guy W (1976) Clinical global impressions. ECDEU assessment manual for psychopharmacology, revised edn. Department of Health, Education, and Welfare, Rockville, pp 218–222
- Howe M, Price I (2001) Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia. Int Psychogeriatr 13:465–475
- Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease. Psychopharmacology 108:485–494
- Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, Sherman SE, Cleveland M, Antonnucio DO, Hartman N, McGovern PG (1996) The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335:1792–1798 CrossRef
- Kellar KJ, Whitehouse PJ, Martino-Barrows AM, Marcus K, Price DL (1987) Muscarinic and nicotinic cholinergic binding sites in Alzheimer’s disease. Brain Res 436:62–68 CrossRef
- Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of nicotine on Parkinson’s disease. Brain Cogn 43:274–282
- Levin ED, Rezvani AH (2001) Nicotinic involvement in cognitive function in rats. In: Levin ED (ed) Nicotine and the nervous system. Methods in neuroscience. CRC Press, New York
- Levin E, Rezvani A (2002) The promise of nicotinic treatment for cognitive dysfunction. Curr Drug Targets 1:423–431
- Levin ED, Rose JE (1995) Acute and chronic nicotinic interactions with dopamine systems and working memory performance. In: Lajtha A, Abood L (eds) Functional diversity of interacting receptors. The New York Academy of Sciences, New York, pp 218–221
- Levin ED, Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138:217–230 CrossRef
- Levin ED, Lee C, Rose JE, Reyes A, Ellison G, Jarvik M, Gritz E (1990) Chronic nicotine and withdrawal effects on radial-arm maze performance in rats. Behav Neural Biol 53:269–276
- Levin ED, Briggs SJ, Christopher NC, Rose JE (1992) Persistence of chronic nicotine-induced cognitive facilitation. Behav Neural Biol 58:152–158
- Levin E, Wilson W, Rose J, McEvoy J (1996a) Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15:429–436
- Levin ED, Conners CK, Sparrow E, Hinton S, Meck W, Rose JE, Ernhardt D, March J (1996b) Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123:55–63
- Levin ED, Conners CK, Silva D, Hinton SC, Meck W, March J, Rose JE (1998) Transdermal nicotine effects on attention. Psychopharmacology 140:135–141
- Levin ED, Conners CK, Silva D, Canu W, March J (2001) Effects of chronic nicotine and methylphenidate in adults with ADHD. Exp Clin Psychopharmacol 9:83–90
- Min S, Moon I, Ko R, Shin H (2001) Effects of transdermal nicotine on attention and memory in healthy elderly nonsmokers. Psychopharmacology 159:83–88 CrossRef
- Newhouse PA, Kelton M (2000) Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. Pharm Acta Helv 74:91–101 CrossRef
- Newhouse P, Potter A, Kelton M, Corwin J (2001) Nicotinic treatment of Alzheimer’s disease. Biol Psychiatry 49:268–278 CrossRef
- Nordberg A (1994) Human nicotinic receptors—their role in aging and dementia. Neurochem Int 25:93–97 CrossRef
- Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edwardson JA, Fairbairn A, Blessed G (1987) Nicotinic receptor abnormalities in Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psychiatry 50:806–809
- Provost SC, Woodward R (1991) Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology 104:536–540
- Reeves D, Bleiberg J, Spector J (1993a) Validation of the ANAM battery in multi-center head injury rehabilitation studies. Arch Clin Neuropsychol 8:356
- Reeves D, Kane R, Winter K, Raynsford K, Pancella T (1993b) Automated neuropsychological assessment metrics (ANAM): test administrator’s guide, version 1.0. Missouri Institute of Mental Health, St. Louis, MO
- Rusted J, Graupner L, Oconnell N, Nicholls C (1994) Does nicotine improve cognitive function? Psychopharmacology 115:547–549
- Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of Alzheimer type. Br J Psychiatry 154:797–800
- Seidl R, Tiefenthaler M, Hauser E, Lubec G (2000) Effects of transdermal nicotine on cognitive performance in Down’s syndrome. Lancet 356:1409–1410 CrossRef
- Shimohama S, Taniguchi T, Fujiwara M, Kameyama M (1986) Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 46:288–293
- Snaedal J, Johannesson T, Jonsson JE, Gylfadottir G (1996) The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer’s disease. Dementia 7:47–52
- Warburton DM, Arnall C (1994) Improvements in performance without nicotine withdrawal. Psychopharmacology 115:539–542
- Wesnes K, Revell A (1984) The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 84:5–11
- White HK, Levin ED (1999) Chronic four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease. Psychopharmacology 143:158–165
- Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, Kellar KJ (1988) Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 45:722–724
- Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, McFalls E, Kovera C, McCarten JR (1995a) Nicotine patches in Alzheimer’s disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 51:509–514
- Wilson AL, McCarten JR, Langley LK, Bauer T, Monley J, Rottunda S, McFalls E, Kovera C (1995b) Transdermal nicotine administration in Alzheimer’s disease: effects on cognition, behavior and cardiac function. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM (eds) Research advances in alzheimer’s disease and related disorders. John Wiley and Sons, Ltd., Chichester, pp 305–314
- Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment
Volume 171, Issue 4 , pp 465-471
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Age-associated memory impairment
- Nicotine skin patches
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine, Duke University Medical Center, Box no. 3003, Durham, NC 27710, USA
- 4. Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA
- 5. Geriatric Research, Education and Clinical Center, VAMC, Durham, NC, USA
- 2. Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box no. 3412, Durham, NC 27710, USA
- 3. Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA